Circulating miR-330-3p in Late Pregnancy is Associated with Pregnancy Outcomes Among Lean Women with GDM by Pfeiffer, Shona et al.
1Scientific RepoRtS |          (2020) 10:908  | https://doi.org/10.1038/s41598-020-57838-6
www.nature.com/scientificreports
Circulating miR-330-3p in Late 
Pregnancy is Associated with 
Pregnancy Outcomes Among Lean 
Women with GDM
Shona pfeiffer1,4, Begoña Sánchez-Lechuga2,4, Paul Donovan1, Luise Halang1, 
Jochen H. M. prehn1, Antonio campos-caro  2, Maria M. Byrne1,3 & Cristina López-tinoco2*
Gestational Diabetes Mellitus (GDM) is characterised by insulin resistance accompanied by reduced 
beta-cell compensation to increased insulin demand, typically observed in the second and third 
trimester and associated with adverse pregnancy outcomes. There is a need for a biomarker that 
can accurately monitor status and predict outcome in GDM, reducing foetal-maternal morbidity 
and mortality risks. To this end, circulating microRNAs (miRNAs) present themselves as promising 
candidates, stably expressed in serum and known to play crucial roles in regulation of glucose 
metabolism. We analysed circulating miRNA profiles in a cohort of GDM patients (n = 31) and 
nondiabetic controls (n = 29) during the third trimester for miRNA associated with insulin-secretory 
defects and glucose homeostasis. We identified miR-330-3p as being significantly upregulated in lean 
women with GDM compared to nondiabetic controls. Furthermore, increased levels of miR-330-3p 
were associated with better response to treatment (diet vs. insulin), with lower levels associated with 
exogenous insulin requirement. We observed miR-330-3p to be significantly related to the percentage 
of caesarean deliveries, with miR-330-3p expression significantly higher in spontaneously delivered 
GDM patients. We report this strong novel association of circulating miR-330-3p with risk of primary 
caesarean delivery as a pregnancy outcome linked with poor maternal glycaemic control, strengthening 
the growing body of evidence for roles of diabetes-associated miRNAs in glucose homeostasis and 
adaptation to the complex changes related to pregnancy.
Gestational Diabetes Mellitus (GDM) is diagnosed as the development of hyperglycaemia during the second or 
third trimester in pregnant women not previously diagnosed with diabetes1. The global epidemic of obesity and 
diabetes has resulted in an increase in the prevalence of diabetes mellitus in women of childbearing age and esti-
mates currently place 5% to 20% of pregnancies as affected by GDM worldwide, due to differences in population 
demographics, diagnostic criteria, screening methods and maternal lifestyle2. The significant risk-associations 
between hyperglycaemia not considered to be within the diagnostic range for overt diabetes and adverse perinatal 
and maternal outcomes require more accurate measures for monitoring status and predicting outcome in GDM3.
The pathophysiology of GDM manifests as a result of the progressive insulin resistance (IR) and subsequent 
increased insulin secretion requirement that occurs during normal pregnancy4. As a result, most women with 
GDM develop pancreatic beta-cell dysfunction secondary to IR, resulting in impaired glucose tolerance in a 
setting of IR similar to that of T2DM5. However, the possible causes of beta-cell dysfunction and IR are not well 
described, including the contributions of autoimmune and monogenic factors. Meta-analysis of gene expression 
profiles has indicated that the transcriptome profile in GDM is more similar to that of autoimmune type 1 diabe-
tes mellitus (T1DM) than to T2DM6. Cross-sectional studies on small cohorts of women with GDM have shown 
that the prevalence of monogenic GCK mutations associated with impaired glucose regulation is between 0% and 
5%7–9 and HNF1A or HNF4A loss-of-function mutations associated with beta-cell dysfunction contribute to <1% 
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of cases10. Taken together, the ability to diagnose GDM distinct from undiagnosed or incidental development of 
other forms of diabetes prior to, or during, pregnancy represents a significant challenge11.
Systemic regulation of glucose homeostasis requires concerted actions of tightly regulated signalling pathways. 
MicroRNAs (miRNAs) are well known to play key roles in the modulation of such pathways through base pairing 
of target mRNAs, leading to repression of protein production or mRNA degradation12. Evidence has implicated 
miRNAs as playing crucial roles in glucose metabolism13, pancreatic development14,15, insulin secretion15–18 and 
insulin deficiency19. Furthermore, the secretion of miRNAs and easy detection in biofluids has resulted in exam-
ination of unique miRNA differential expression profiling of urine, serum and whole blood as diagnostic bio-
markers for disease progression20–22. Previously we have demonstrated significant increases in extracellular novel 
diabetes-linked miRNAs miR-224 and miR-103-3p in biofluids of patients with HNF1A-MODY primary beta-cell 
dysfunction, capable of differentiating these patients from T2DM23,24. Such ease of access and a minimally inva-
sive approach places circulating miRNA profiling as a promising novel clinical approach in the progression and 
management of GDM and associated outcomes.
MiR-103-3p dysregulation has been widely reported by us and others in HNF1A-MODY, T1DM and T2DM23–25. 
Elevated levels detected in a leptin-deficient ob/ob mouse model of obesity associated with T2DM were shown to 
negatively regulate insulin sensitivity while inhibition of miR-103-3p resulted in increased glucose tolerance and 
a reduction in hyperglycaemia19. Furthermore, target analysis and miRNA-modulation has highlighted roles for 
miR-103-3p in peripheral insulin sensitivity19. Elevated expression of miR-224 in HNF1A-MODY and patients 
with T1DM, first reported by us as a novel miRNA in the field of diabetes, presents a potential role for miR-224 
in beta-cell failure, distinct from relative insulin deficiency. Akehurst et al. previously reported miR-206 as a 
novel prognostic pregnancy-associated circulating miRNA associated with the development of preeclampsia as 
a complication of pregnancy26. MiR-206 has also been reported to play a central role in glucose homeostasis reg-
ulation through modulation of glucokinase activity, negatively regulating glucose-stimulated insulin secretion27. 
Furthermore, the therapeutic potential of miR-206 in settings of hyperglycaemia has been reported, elucidating 
mechanistic roles in the inhibition of glucose production and lipogenesis and promotion of insulin signalling28. 
Of particular interest, dysregulation of miR-330-3p has been observed in a small cohort of pregnant women 
diagnosed with GDM29. Despite the emergence of compelling evidence for miRNAs such as these having relevant, 
functional roles in the pathogenesis of GDM, circulating miRNAs remain poorly considered in this setting.
The mounting evidence for central roles of miRNAs in important diabetes-associated pathways with impli-
cations for glucose homeostasis further supports profiling of miRNA dysregulation in GDM as a predictor of 
pregnancy outcome linked to disease severity and progression. Altered circulating miRNAs associated with the 
development and pathogenesis of insulin secretory defects and impaired glucose processing in such a clinically 
heterogeneous and often asymptomatic cohort would be invaluable in monitoring glycaemic management, treat-
ment response and progression, allowing for tighter control impacting on associated complications. Therefore, 
we aimed to establish a signature of these potentially significant diabetes-associated miRNAs in lean women with 
GDM without risk factors for IR for improved management and outcome prediction in GDM.
Results
GDM and nondiabetic cohort profiling. Serum from GDM patients (n = 31) and age- and body mass 
index (BMI)-matched nondiabetic (n = 29) cohorts was collected for profiling. The clinical characteristics of 
both cohorts are presented in Table 1. Weight gain was higher in nondiabetic controls (11.8 ± 4.1) compared to 
the GDM cohort (9.3 ± 4.1) with no significant differences observed in other variables. Within the GDM cohort, 
twelve (38%) women were treated with diet and nineteen (61%) received insulin. Insulin-treated GDM patients 
were observed to have significantly increased mean fasting glucose levels (102 ± 17.7 vs 79.9 ± 6.7, p < 0.001) and 
HbA1c levels (5.13 ± 0.48 vs 4.96 ± 0.30, p = 0.01) compared with the diet-treated group. There were no signif-
icant differences in the rest of the analytical and clinical variables and the obstetrical or perinatal complications 
between groups treated with insulin versus diet.
miRNA profiling in the serum of GDM patients: miR-330-3p levels are elevated in the serum of 
patients with GDM. We performed miRNA absolute quantitative PCR analysis of the expression of four 
miRNAs of interest in the serum from women with GDM (n =31) compared with healthy controls (n = 29). 
Here we found miR-224 to be detectable in the serum of both GDM (median [IQR], 78205 [32239–175925] cop-
ies, n = 26) and control (median [IQR], 60298 [19595–100208] copies, n = 20) cohorts, although no significant 
difference was determined between groups (Fig. 1(a)). Levels of miR-103-3p were also detectable in both GDM 
(median [IQR], 30804 [16991–82426] copies, n = 26) and control (median [IQR], 28588 [11769–95796] cop-
ies, n = 20) cohorts, but similar to miR-224, no significant difference was observed in expression levels between 
groups (Fig. 1(b)). Next we examined expression of miR-206, shown to play a role in glucose tolerance and home-
ostasis27. Similar to miR-103-3p and miR-224, while levels of miR-206 were detectable in both GDM (median 
[IQR], 4048 [2541–7195] copies, n = 31) and control (median [IQR], 5109 [2480–11028] copies, n = 29) groups, 
they were not found to differ significantly (Fig. 1(c)). Finally, we examined expression levels of miR-330-3p as 
a potential GDM-associated miRNA. Interestingly, we found significantly increased serum expression of miR-
330-3p in our GDM cohort, demonstrating a 5.2-fold difference in mean miRNA expression (p = 0.003, Mann–
Whitney U test) in GDM patients (median [IQR], 656943 [16149–1355000] copies, n = 31) compared to control 
(median [IQR], 20098 [8734–50016] copies, n = 29) (Fig. 1(d)).
Multivariate analysis was performed based on GDM diagnosis as the dependent variable and independent 
variables considered to be of clinical significance or statistically significant based on univariate analysis. The 
results of this final model are presented in Table 2, and indicate that increased circulating serum miR-330-3p (OR: 
1.99) is associated with onset or development GDM and suggests miR-330-3p is associated with phenotypic onset.
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Levels of miR-330-3p are associated with type of treatment and delivery in women with GDM. 
In assessing the relationships between the different miRNA and obstetric and perinatal variables in GDM 
patients, we observed that the levels of miR-330-3p were significantly related to the percentage of caesar-
ean deliveries (10.6 ± 2.7; p = 0.012) (Table 3, Fig. 2(a)). Spontaneously delivered GDM patients displayed 
significantly higher expression of miR330-3p (median [IQR], 1012000 [59518–1640000] copies, n = 19) 
compared to GDM patients delivered by primary caesarean section, observed to have significantly lower 
copy number (median [IQR], 19278 [5677–817926] copies, n = 12). Furthermore, we observed signifi-
cantly increased circulating miR-330-3p levels in spontaneously delivered GDM patients (median [IQR], 
1012000 [59518–1640000] copies, n = 19) compared to spontaneously delivered control (median [IQR], 
23160 [8580–43841] copies, n = 24; p = 0.001, Kruskal-Wallis test) (Fig. 2(b)). Significantly increased lev-
els of circulating miR-330-3p were also observed in GDM patients treated by diet (median [IQR], 946252 
[484236–1517000] copies, n = 12) but not those treated by insulin (median [IQR], 59518 [12967–1355000] 
copies, n = 19) when compared to nondiabetic controls (median [IQR], 20098 [8734–50016] copies, n = 29; 
p = 0.004, Kruskal-Wallis test)(Fig. 3).
In order to fully demonstrate the significant association of miR-330-3p and risk of primary caesarean delivery 
in GDM patients, multivariate analysis was performed based on primary caesarean delivery as the dependent 
variable and the potential of confounding by factors that might be associated with both miR-330-3p and primary 
caesarean delivery as independent variables. The results of this final model are presented in Table 4, and indicate 
a protective effect for circulating serum miR-330-3p (OR: 0.4) for the presence of primary caesarean delivery. 
Patients with previous caesarean section were excluded from primary caesarean delivery analysis.
Identification of miR-330-3p targets and pathway enrichment. 1,031 gene targets of miR-330-3p 
were predicted using TargetScan. The predicted miR-330-3p target genes were analysed using the gene ontology 
enrichment analysis tool. In total, 24 databases were analysed, the full results of which are available in supple-
mentary file EnrichR_Analysis.xlsx. A Kyoto Encyclopedia of Genes and Genomes (KEGG)30 pathway analysis 
revealed 12 pathways overrepresented in the predicted gene targets of miR-330-3p, including the insulin signal-
ling pathway (p-adj <0.05). 16 proteins associated with this pathway are present in the TargetScan predictions. 
The analysis of the databases ‘InterPro Domains 2019’, ‘Pfam domains’, and ‘Panther 2016’ displayed enrichment 
of Cadherin domains/pathways (Fig. 4). Panther 2016 also revealed a significant number of miR-330-3p target 
genes are associated with cholecystokinin receptor (CCKR) signalling. Furthermore, several databases analysed 
by EnrichR (KEGG, Panther, Reactome) revealed a relationship between the Wnt signalling pathway and the 
predicted miR-330-3p targets. A kinase enrichment analysis showed that Glycogen synthase kinase 3 (GSK3), a 
protein involved in Wnt and insulin signalling, shares a significant number of phosphorylation targets with the 
TargetScan gene predictions. In addition, GSKIP (GSK3B Interacting Protein), a negative regulator of GSK3-beta, 





(n = 29) p value
Age (y) 31.9 ± 1.8 31.0 ± 3.6 NS
Pre-gestational BMI (kg/m2) 22.5 ± 1.8 22.3 ± 1.8 NS
DM family history n (%) 14 (51.3) 14 (48.3) NS
GDM personal history n (%) 9 (29) 3 (10) NS
Systolic BP (mmHg) 106.9 ± 12.3 106.8 ± 18 NS
Diastolic BP (mmHg) 64 ± 9 61 ± 6 NS
Basal glucose (mg/dl) 92.5 ± 13 83 ± 4 0.01
Total- cholesterol (mmol/l) 244.4 ± 46.1 240.2 ± 30.1 NS
LDL- cholesterol;(mmol/l) 142.4 ± 44.6 139.3 ± 10.7 NS
HDL- cholesterol (mmol/l) 71.1 ± 16.4 77.6 ± 26.3 NS
TG (mmol/l) 193.8 ± 63.1 217.2 ± 68.0 NS
Weight gain (kg) 9.3 ± 4.1 11.8 ± 4.1 0.03
Gestational age at delivery (wk) 39.1 ± 1.3 39.2 ± 1.2 NS
Caesarean section n (%) 18 (39.0) 5 (18) 0.06
Birth weight (g) 3202 ± 589 3307 ± 545 NS
Macrosomia n (%) 3 (14.1) 3 (9) NS
HbA1c 5.4 ± 0.36 4.8 ± 0.33 0.02
LGA n (%) 3 (10) 3 (9) NS
SGA n (%) 2 (7) 5 (16) NS
Table 1. Demographic, clinical, laboratory variables and obstetric and perinatal outcomes in women with 
GDM and controls. Data are presented as means ± SD or n (%). BMI, body mass index; BP, blood pressure; DM, 
diabetes mellitus; LGA, large for gestational age; SGA, small for gestational age.
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Discussion
Given the challenges of GDM management and outcome prediction in the setting of increased global incidence, 
undiagnosed and untreated forms of diabetes, there is a need for a biomarker that can accurately monitor GDM 
pathogenesis and reduce foetal-maternal morbidity and mortality risks. To this end, circulating microRNAs 
present themselves as promising candidates, stably expressed in serum and known to play crucial roles in pan-
creatic development14,15, insulin secretion15–17 and insulin deficiency19,31. Furthermore, evidence from mater-
nal blood profiling in the first weeks of pregnancy demonstrating increasing concentrations of placental and 
trophoblast-derived extracellular vesicles (EVs) implicates circulating microRNAs in maternal environmental 
homeostasis in response to stimuli such as high glucose concentration32–34.
Figure 1. Detection of diabetes-associated circulating serum miRNAs associated with glucose tolerance 
and homeostasis in the serum of patients with GDM and non-diabetic controls. (a), miR-224-5p levels were 
detectable in serum of control (median [IQR], 60298 [19595–100208] copies, n = 20) and gestational diabetes 
mellitus (GDM) patients (median [IQR], 78205 [32239–175925] copies, n = 26). Significance determined 
by Mann–Whitney U test, p = 0.215. (b), miR-103-3p levels detected in serum of control (median [IQR], 
28588 [11769–95796] copies, n = 20) and gestational diabetes mellitus (GDM) patients (median [IQR], 30804 
[16991–82426] copies, n = 26). Significance determined by Mann–Whitney U test, p = 0.763. (c), miR-206 levels 
were detected in serum of control (median [IQR], 5109 [2480–11028] copies, n = 29) and gestational diabetes 
mellitus (GDM) patients (median [IQR], 4048 [2541–7195] copies, n = 31). Significance determined by Mann–
Whitney U test, p = 0.420. (d), miR-330-3p levels detected in the serum of gestational diabetes mellitus (GDM) 
patients (median [IQR], 656943 [16149–1355000] copies, n = 31) were found to be significantly higher than 
those of nondiabetic controls (median [IQR], 20098 [8734–50016] copies, n = 29). Significance determined by 
Mann–Whitney U test, p = 0.003.
Variables OR Z-score p-value 95% CI
Age 0.9 −0.6 0.8 0.5-1.6
Pre-gestational BMI 1.2 0.2 0.6 0.5-2.7
miR-330-3p 1.99 0.6 0.03 1.06-3.7
miR-224-5p 4.66 1.5 0.9 0.00-5.7E + 15
miR-206 1.09 0.09 0.9 0.02-57
miR-103-3p 1.051 0.05 0.9 0.2-5.3
TG 1.01 0.1 0.2 0.9-1.03
Weight gain 0.8 −0.1 0.4 0.6-1.2
Constant 0.00 −15.9 0.6
Table 2. Multivariate logistic regression for GDM (final model). OR, odd ratio; 95% CI, 95% confidence 
interval.
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Previously we demonstrated upregulation of miR-103-3p and miR-224 in individuals with an insulin-secretory 
defect as seen in T1DM and HNF1A-MODY, which were not found here to be significant in our GDM cohort23,24. 
Pregnancy itself is considered to be a diabetogenic endocrine–metabolic adaptation process, with altered glucose 
metabolism resulting in the progressive development of IR and consequent increased postprandial glucose, circu-
lating lipids and beta-cell demand35,36. Beta-cell adaptation to pregnancy, increasing capacity through expansion 
of cell mass and secretion, is associated with alterations to the endogenous miRNA profile in response to the 
physiological changes of pregnancy37. Several islet microRNAs have been reported to contribute to this adaptive 










miRNA-330-3p 10.6 ± 2.7* 12.8 ± 1.9 10.5 ± 2.5 12.1 ± 2.4
miRNA-224-5p 2.3 ± 0.1 2.4 ± 0.1 2.4 ± 0.7 2.1 ± 0.1
miRNA-206 10.8 ± 0.9 11.4 ± 1.2 11.7 ± 0.2 11.1 ± 1.1
miRNA-103-3p 9.9 ± 0.9 10.7 ± 1.1 10.8 ± 0.8 10.4 ± 1.1
Table 3. Relationships between levels of miRNA and the percentage of macrosomia and Caesarean delivery. 
Data expressed as mean ± SD; *p <0.05.
Figure 2. Circulating miR-330-3p levels are associated with risk of primary caesarean section in women with 
GDM. (a), analysis of miR-330-3p expression in GDM cohort by incidence of vaginal (spontaneous) delivery 
(median [IQR], 1012000 [59518–1640000] copies, n = 19) and those delivered by caesarean section (median 
[IQR], 19278 [5677–817926] copies, n = 12). Significance determined by Mann-Whitney U Test, p = 0.012. (b), 
analysis of miR-330-3p expression (copies) by incidence of vaginal (spontaneous) delivery: control, (median 
[IQR], 23160 [8580–43841] copies, n = 24), GDM (median [IQR], 1012000 [59518–1640000] copies, n = 19) 
and caesarean delivery: control (median [IQR], 9957 [5216–834332] copies, n = 5), GDM (median [IQR], 
19278 [5677–817926] copies, n = 12). Significance determined by Kruskal-Wallis Test adjusted by Bonferroni 
correction for multiple tests, p = 0.001.
Figure 3. Levels of miR-330-3p are associated with type of treatment. Analysis of miR-330-3p expression 
(copies) in GDM patients treated by diet (median [IQR], 946252 [484236–1517000] copies, n = 12) or insulin 
(median [IQR], 59518 [12967–1355000] copies, n = 19) compared to non-diabetic controls (median [IQR], 
20098 [8734–50016] copies, n = 29). Significance determined by Kruskal-Wallis Test, p = 0.004.
6Scientific RepoRtS |          (2020) 10:908  | https://doi.org/10.1038/s41598-020-57838-6
www.nature.com/scientificreportswww.nature.com/scientificreports/
we would observe differences in miR-103-3p and miR-224 between nondiabetic controls and diabetics with an 
insulin-secretory defect, it is likely that these physiological adaptive responses to pregnancy are why we do not 
observe differences in these miRNAs in our GDM cohort compared to nondiabetic pregnant controls.
Previous work by Sebastiani et al. identified increased levels of miR-330-3p in women diagnosed with GDM 
(n = 21) compared to nondiabetic subjects (n = 10) at 28th–33th week of gestation29. Here, we confirmed upreg-
ulation of circulating miR-330-3p in a larger GDM cohort (n = 31) compared to a matched nondiabetic cohort 
(n = 29). Interestingly, further analysis found significantly elevated miR-330-3p levels in GDM patients treated 
by diet compared to those treated by insulin, a finding found to be independent of incidence of T2DM in a 
first-degree relative. The increase in circulating miR-330-3p observed in the diet-treated GDM patient group is 
Variables OR Z-score p-value 95% CI
Age 0.7 −0.3 0.3 0.3-1.4
Pre-gestational BMI 1.4 0.3 0.2 0.7-2.6
Pregnancies 0.7 −0.2 0.6 0.1-2.9
miR-330-3p 0.4 −0.8 0.02 0.2-0.8
Glucose 0.9 −0.2 0.6 0.8-1.06
Gestational delivery 
weeks 0.8 −0.1 0.4 0.6-1.2
Constant −15.9 0.1
Table 4. Multivariate logistic regression for Cesarean Section (final model). OR, odd ratio; 95% CI, 95% 
confidence interval.
Figure 4. MiR-330-3p targets multiple overlapping KEGG pathways. (a), multiple pathways were identified 
using KEGG pathway analysis. Edges are coloured based on their pathway of origin. (b,c), bar plots showing 
the −log10 of the adjusted p-values of significantly enriched (p-adj < 0.05) Panther pathways and kinase 
enrichment analysis terms, respectively, for predicted targets of miR-330-3p.
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further indicative that miR-330-3p dysregulation signals an increased beta-cell adaptive response to developing 
IR as seen in GDM. This is supported by Sebastiani et al., who reported an inverse correlation between insulinae-
mia and circulating miR-330-3p levels in GDM patients, but not in nondiabetic controls29. Insulin levels within 
the range of normal nondiabetic controls were observed to correlate with increased circulating miR-330-3p com-
pared to hyperinsulinemia, observed to correlate with low levels of miR-330-3p in women with GDM. Current 
treatment strategies in the initial management of women with GDM centre on medical nutrition therapy, however 
this approach remains a challenging treatment with regard to adherence in GDM39,40. Furthermore, emphasis on 
restriction of dietary carbohydrate and a corresponding increased reliance on fat can result in exacerbation of 
maternal IR41–44. Diet-treated GDM patients with increased levels of circulating miR-330-3p may achieve better 
glycaemic control, with levels of miR-330-3p decreasing with increasing disease severity and exogenous insulin 
requirement. GDM patients receiving nutrition therapy with significantly or progressively lower levels of miR-
330-3p may be candidates for progression to insulin therapy or future T2DM development due to progressive 
decline in compensatory insulin secretion in a setting of uncontrolled hyperglycaemia and increased IR, resulting 
in a persistent and progressive metabolic load45.
Importantly, further linking miR-330-3p with diabetic phenotype severity, on measurement of pregnancy 
outcomes we observed a significant correlation between miR-330-3p levels and percentage of primary caesarean 
deliveries, with increased miR-330-3p expression significantly higher in spontaneous delivery in GDM patients 
but not those delivered by caesarean section when compared to spontaneously-delivered nondiabetic controls. 
Significant associations between poor maternal glycaemic control during pregnancy and adverse outcomes are 
well established, and glucose levels are a significant predictor of primary caesarean delivery3. As a known GDM 
complication related to hyperglycaemia during pregnancy, this novel finding that lower miR-330-3p is associated 
with higher risk of primary caesarean delivery suggests a better outcome associated with increased miR-330-3p, 
and further strengthens the role for miR-330-associated with disease severity and control, impacting on preg-
nancy outcomes.
The heterogeneous aetiology of GDM and associated risk factors, in concert with genetic predisposition and 
the degree to which individual patients can achieve glycaemic control and insulin secretory requirements, place 
miRNAs in an attractive position as clinically relevant targets, regulating multiple genes in diverse biological 
pathways46,47. Roles in beta-cell function and preservation in GDM, including proliferation, hyperplasia and 
hypertrophy, are balanced against progressive dysfunction and beta-cell exhaustion in the challenge to compen-
sate for increased insulin demand, resulting in beta-cell demise and progression of the diabetic phenotype48–50. As 
such, these findings highlight miR-330-3p as a potential biomarker and regulatory target in the pathogenesis of 
GDM. To examine potential mechanisms though which miR-330-3p might mediate such processes in the control 
of hyperglycaemia, Sebastiani et al. highlighted two experimentally validated targets of miR-330-3p: E2F tran-
scription factor 1 (E2F1), facilitating glucose homeostasis through upregulation of beta-cell proliferation, insulin 
secretion and glucose tolerance51, and cell division cycle 42 (CDC42), a potent modulator of insulin secretion and 
importantly, second-phase insulin release52,53.
We carried out pathway enrichment analysis to further elucidate potential pathways regulated by miR-330-3p, 
revealing significant overrepresentation of cadherin signalling. Calcium-dependent aggregation of islet cells is 
known to be mediated by E-cadherin (uvomorulin)54. A study from 2015 found that specific cadherins adhere to 
beta-cells, and that this process promotes insulin secretion55. Our analysis also revealed a significant number of 
miR-330-3p target genes associated with CCKR signalling. Gastric hormones cholecystokinin (CCK) and gastrin 
are key regulators of the digestion of fats and proteins, and activation of CCKR signalling has been shown to 
improve glucose tolerance and insulin resistance56–58. Of particular interest, our analyses revealed a relationship 
between Wnt signalling and predicted miR-330-3p targets. Wnt signalling is associated with T2DM through 
Wnt signalling pathway effector TCF7L2, implicated as one of the strongest candidate genes in the pathogenesis 
of impaired beta-cell function and insulin secretion in T2DM59,60. A kinase enrichment analysis showed that 
Glycogen synthase kinase 3 (GSK3), involved in the regulation of Wnt and insulin signalling, shares a significant 
number of phosphorylation targets with the TargetScan gene predictions. GSK3 is a negative regulator of insu-
lin signalling, strongly linked with insulin resistance and numerous studies targeting GSK3 provide compelling 
evidence for GSK3-inhibition improving insulin sensitivity as a therapeutic target in T2DM61–65. Furthermore, 
GSKIP (GSK3B Interacting Protein), a negative regulator of GSK3-beta, is a predicted target of miR-330-3p and 
of significant interest, increased levels of adipose and skeletal muscle GSK3-beta have been observed in GDM 
patients66. Given our findings in our GDM cohort, miR-330-3p is uniquely poised in the coordination of an 
adaptive response to progressive IR and subsequent increased insulin demand. Modulation of these target genes 
in response to onset of hyperglycaemia and diabetic phenotype may play key roles in maternal glycaemic home-
ostasis, disease progression and pregnancy outcomes, with individuals expressing higher levels of miR-330-3p 
achieving better outcomes, glycaemic management and lower risk for future progression. Lower serum miR-
330-3p is potentially indicative of inadequate beta-cell adaptation to peripheral IR, resulting in pathological glu-
cose intolerance and hyperglycaemia observed in GDM patients requiring treatment by insulin4.
We report upregulation of circulating miR-330-3p associated with maternal glycaemic management and preg-
nancy outcomes in patients with GDM. This further strengthens the growing body of evidence for miRNAs such 
as miR-330-3p playing pivotal roles mediating both disease pathology and adaptation to the complex changes 
related to normal pregnancy, highlighting their potential as novel targets in conditions such as GDM. We report 
the significant association of miR-330-3p with risk of primary caesarean delivery as a pregnancy outcome well 
established to be linked with poor maternal glycaemic control, and propose that miR-330-3p levels associated 
with pregnancy outcome merit further research, with implications for within-cohort discrimination linked to 
disease severity, functional beta-cell adaptation to peripheral IR and exogenous insulin requirement. We propose 
that circulating levels of miR-330-3p may ultimately help guide the choice of a personalized therapy in GDM, 
associated with pregnancy outcomes and/or severity and type of treatment in lean women with GDM.
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Methods
Patient cohorts. Pregnant women (n = 31 GDM patients, n = 29 matched nondiabetic controls) attending 
the Endocrinology and Pregnancy Clinic, Puerta del Mar University Hospital, Cádiz were recruited during the 
third trimester (26–30 weeks) and followed throughout the pregnancy. Consecutive participants with GDM who 
met the eligibility criteria were enrolled and nondiabetic controls were age- and BMI-matched to each case. 
The study and protocol were approved by the Puerta del Mar Hospital Research Ethics Board and carried out in 
accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from all 
participants.
Subjects of study. Inclusion criteria. Universal screening with 50 g glucose load was employed for all par-
ticipants. Women with a pre-gestational BMI < 25(kg/m2) in the second or third trimester were diagnosed with 
GDM according to the criteria of the National Diabetes Group (NDDG), presenting two abnormally high values 
on a 3-hour oral glucose tolerance test (OGTT). Diagnostic thresholds were <105, 190, 165 and 145 mg/dl at 
fasting, 60, 120 and 180 min, respectively. Nondiabetic control participants had blood glucose <140 mg at 60 min 
post-glucose load. Exclusion criteria: Women with a pre-gestational BMI>25 (kg/m2); chronic hypertension, or 
who are treated with antihypertensive drugs; diagnosis of placental insufficiency, pre-gestational diabetes, chronic 
underlying systemic disease or acute infectious process; smoking; lack of informed consent; positive glutamate 
dehydrogenase (GAD), and islet antigen 2 (IL-2) antibodies.
Study variables. Clinical and demographic variables. At the time of inclusion in the study, the clinical 
and demographic characteristics of the participating women were collected. The data are taken from the clinical 
history; family history of diabetes, age, obstetric history, parity, height, previous and current weight, body mass 
index, and gestational age. Throughout gestation, data was collected regarding gestational complications, values 
of blood pressure, levels of HbA1c, type of treatment (diet or insulin), type of delivery (eutocic, dystocic, caesar-
ean), week of end of gestation, weight of the newborn, Apgar test and complications of newborn (hypoglycaemia, 
hyperbilirubinemia, infections, admission to ICU).
Analytical variables. A venous blood sample for biochemical analyses was taken at the time of inclusion into 
the study, in all cases following a minimum of 8 hours fasting. The blood was maintained at room temperature 
(RT). For serum collection, blood samples are kept at RT for a minimum of 30 to a maximum of 60 min to allow 
a clot to form. The samples were then centrifuged at 4 °C, serum was distributed in aliquots and stored at −80 °C.
Glucose was determined in venous blood using the Modular DPD biochemical system (Roche Diagnostics). 
HbA1c was measured in the Cobas Integra 700 auto-analyzer (Roche Diagnostics) using an immunoturbidimet-
ric method for completely haemolyzed, anti-coagulated blood. The laboratory reference range for healthy indi-
viduals was 4.5–5.7%. Lipid profiles, including total cholesterol (Total-chol), triglycerides (TG), LDL-cholesterol 
(LDL-chol) and HDL-cholesterol (HDL-chol) are quantified in the Modular DPD biochemical auto-analyzer 
using enzymatic colorimetry.
RNA isolation from serum. Total RNA enriched with miRNAs was isolated from serum samples (200 μl), 
taken from 31 patients with GDM and 29 nondiabetic control pregnant women, using the miRNeasy Serum/
Plasma kit (Qiagen) according to manufacturer's instructions. Synthetic C. elegans miRNA (cel-miR-39) spike-in 
control was added (50 pmol) to each sample for input normalisation prior to RNA isolation.
Reverse transcription and quantitative real-time-PCR measurement of circulating miR-
NAs. Measurement of circulating miRNAs was carried out as previously described23,24. Briefly, reverse tran-
scription reactions were performed using a fixed input volume of 3 µl serum RNA using the Taqman miRNA 
Reverse Transcription kit (Applied Biosystems) according to the manufacturer's instructions with miRNA-specific 
TaqMan microRNA Assays for miRNAs of interest: hsa-miR-224-5p (assay ID_002099), hsa-miR-103-3p (assay 
ID_000439), hsa-miR-330-3p (assay ID_000544), hsa-miR-206, (assay ID_000510) and cel-miR-39 (assay 
ID_000200) (Applied Biosystems). Quantitative real-time PCR (qPCR) was performed using TaqMan Universal 
PCR Master Mix according to the manufacturer's instructions with an input volume of 1.33 µl RT product in a 
total reaction volume of 20 µl and cycled using the StepOnePlus™ Real-Time PCR System (Applied Biosystems). 
Cycling parameters were as follows: 95 °C for 10 min, followed by 40 cycles of 95 °C 15 s and 60 °C 1 min. All PCR 
amplification reactions were carried out using miRNA-specific Taqman assays. Specific amplification was carried 
out for internal control cel-miR-39 (serum spike-in) for sample input normalisation by a median normalization 
procedure as previously described67. For generation of standard curves, synthetic single-stranded RNA oligo-
nucleotides corresponding to the mature miRNA sequences of each miRNA (Sigma Aldrich) in serial 10-fold 
dilutions were reverse transcribed and run in parallel with the serum samples. Data were normalised to synthetic 
cel-miR-39 spike-in control and target copy number calculated from standard curves. Serum samples were meas-
ured in triplicate using synthetic single-stranded RNA Oligonucleotides as standards to obtain absolute miRNA 
copy numbers which were then normalized against spiked-in synthetic C. elegans miRNA control.
Bioinformatic target prediction and analysis. TargetScan (Release 7.2: March 2018) was used to pre-
dict gene targets for miR-330-3p68. Gene ontology enrichment analysis and alternative analyses were carried 
out using EnrichR (version: January 23rd, 2019)69. An adjusted p-value cut-off of below 0.05 was used to filter 
results. The code used in the bioinformatic analyses can be found here: https://github.com/GiantSpaceRobot/
TargetScan-to-GO.
Statistical analysis. Descriptive statistics of the variables measured are presented as mean, median, stand-
ard deviation (SD) and percentages for the qualitative variables. The Kolmogorov-Smirnov and Shapiro-Wilk 
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statistical tests were used to test the normality of the distributions. Comparisons between quantitative variables 
and groups were with the Student’s t test for parametric variables. Non-parametric variables were evaluated with 
the Mann–Whitney U test or Kruskal-Wallis test. For each categorical variable of interest, associations between 
the dependent and independent variables were determined using the Mantel–Henszel v2 test with Yates’ correc-
tion. The Fisher test was applied in the case that the variable contained less than 5 measurements. The magnitude 
of association was calculated using the odds ratio [OR] with the precision described by the 95% confidence 
interval (95% CI) using the Cornfield approximation. Multivariate analysis was performed using non-conditional 
logistic regression. The stepwise technique was used to select the independent variables introduced into the 
model. The initial criterion for acceptance was a level of significance of p = 0.05. Statistical analyses were per-
formed with the Statistical Package for Social Sciences (SPSS version 25.0 for Windows).
Data availability
All data generated or analysed during this study are included in this published article and its Supplementary 
Information files.
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